Big Pharma is interested in partnering with startup electroCore on commercializing its noninvasive vagus nerve stimulation therapy for migraines and cluster headaches upon FDA approval, company CEO JP Errico says. In a sign that talks may be heating up, electroCore has appointed investment bank Piper Jaffray to advise it.
Maryland CRO ABL has signed a deal with Expression Therapeutics to to handle cell line development studies and help the biotech produce a treatment for hemophilia A.
Pfizer is reaching out to the Google-backed genomics outfit 23andMe to better understand the root causes of inflammatory bowel disease, looking to mine patient data for clues that could bolster its growing pipeline.
Ophthalmology company Oraya Therapeutics will collaborate with researchers from Boston's Dana-Farber Cancer Institute to study applications of its novel radiation therapy against cancer when used in conjunction with gold nanoparticles.
Medtronic hires former senators to lobby against anti-inversion bill and protect acquisition of Covidien
Medtronic quietly hired former Sens. John Breaux (D-LA) and Trent Lott (R-MS) and three others as lobbyists to combat anti-inversion legislation as political anger over the tax saving method mounts, threatening the planned company's planned merger with Covidien.
MannKind has finally nailed down the major league pharma player it always wanted to roll out its inhaled insulin product Afrezza. But after going it alone to nail down an FDA approval on a new therapy that continues to generate heavy skepticism about its marketing potential, the numbers involved so far are still strictly minor league.
Sanofi has reached out to Seattle biotech Immune Design, looking to borrow the company's drug discovery platform to develop new treatments for food allergies.
Japanese drugmaker Astellas Pharma has teamed up with Cancer Research U.K. to join forces on early-stage oncology R&D, working to identify new treatments for pancreatic cancer.
GlaxoSmithKline has again scaled back its expectations for an anti-inflammatory treatment licensed from Galapagos, calling off any plans for late-stage study after a few Phase II miscues dulled the drug's potential.
Quintiles has signed a deal with a Roche diagnostics subsidiary to offer cancer screenings in China, looking to capitalize on the growing market for clinical trials in the country.